YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2025 年第二次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 Un - 致:江苏亚虹医药科技股份有限公司 北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2025 年第二次临时股东大会的法律意见书 嘉源(2025)-04-703 北京市嘉源律师事务所(以下简称"本所")接受江苏亚虹医药科技股份有 限公司(以下简称"亚虹医药"或"公司")的委托,根据《中华人民共和国公 司法》(以下简称"《公司法》")《上市公司股东会规则》(以下简称"《股东 会规则》")等现行有效的法律、行政法规、部门规章、规范性文件(以下简称 "法律法规")以及《江苏亚虹医药科技股份有限公司章程》(以下简称"《公司 章程》"）的有关规定,指派本所律师对公司 2025 年第二次临时股东大会（以 下简称"本次股东大会"）进行见证,并依法出具本法律 ...

Core Viewpoint - The discussion at the "Innovative Progress in Cancer Treatment and New Trends in Drug Development Forum" highlighted the importance of addressing unmet medical needs in women's health, particularly in cervical cancer prevention and treatment [1] Company Summary - Aihong Pharmaceutical is focused on transforming the treatment of cervical precancerous lesions from invasive surgery to non-invasive, fertility-friendly methods [1] - The company's product APL-1702 has entered the second round of technical review by the CDE, indicating that it is in the final stages of preparation for market launch [1] - Aihong Pharmaceutical emphasizes its commitment to continuous innovation in women's health and aims to expedite the approval, access, and application of APL-1702 in the Chinese market [1]

中信证券股份有限公司 关于江苏亚虹医药科技股份有限公司 2025 年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏亚 虹医药科技股份有限公司（以下简称"公司"或"上市公司"）首次公开发行股 票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》、《上海 证券交易所科创板股票上市规则》等相关规定，中信证券履行持续督导职责，并 出具 2025 年半年度（以下简称"本持续督导期间"）跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2025 年 8 月 29 日、2025 年 9 月 3 日对公司进行了现场检 查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财务管理、会计核算和内部审 ...

Group 1 - The core viewpoint of the news is that Yahuang Pharmaceutical has shown significant trading activity and financial performance, with a notable increase in revenue and a high level of financing balance [1][2] - On September 15, Yahuang Pharmaceutical's stock price decreased by 0.86%, with a trading volume of 1.05 billion yuan, and a net financing purchase of 640.96 million yuan [1] - As of September 15, the total financing and securities balance for Yahuang Pharmaceutical was 2.35 billion yuan, which represents 4.69% of its market capitalization, indicating a high level of financing activity [1] Group 2 - As of June 30, the number of shareholders for Yahuang Pharmaceutical increased to 25,500, reflecting a growth of 2.09%, while the average circulating shares per person decreased by 2.05% to 14,857 shares [2] - For the first half of 2025, Yahuang Pharmaceutical reported a revenue of 1.30 billion yuan, marking a year-on-year growth of 61.80%, although the net profit attributable to the parent company was -1.62 billion yuan, an increase of 11.84% compared to the previous period [2] - Among the top ten circulating shareholders, Penghua Medical Technology Stock A ranked as the fourth largest, holding 6.5441 million shares, which is an increase of 891,300 shares from the previous period [2]

江苏亚虹医药科技股份有限公司 2025 年第二次临时股东大会 会议资料 二〇二五年九月 1 | 《关于修订、制定公司部分治理制度的议案》 9 | | --- | 江苏亚虹医药科技股份有限公司 2025 年第二次临时股东大会须知 为了保证股东在本次股东大会依法行使职权，确保股东大会的正常秩序和 议事效率，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》《江苏亚虹医药科技股份有限公司章程》（以下简称"《公 司章程》"）、《江苏亚虹医药科技股份有限公司股东大会议事规则》等有关规 定，江苏亚虹医药科技股份有限公司（以下简称"公司"或"亚虹医药"）特制 定本次股东大会会议须知： 一、为确认出席大会的股东及股东代理人或其他出席者的出席资格，会议 工作人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，请 出席大会的股东或股东代理人或其他出席者提前 30 分钟到达会场签到确认参会 资格。在会议主持人宣布现场出席会议的股东和股东代理人人数及所持有的表 决权数量之前，会议登记应当终止。会议登记终止后进场的股东无权参与现 ...

Core Viewpoint - Yahui Pharmaceutical (688176.SH) is currently experiencing a decline in stock price, closing at 11.51 yuan with a drop of 4.88%, indicating a state of share price below the initial public offering (IPO) price [1] Summary by Relevant Sections Company Overview - Yahui Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an issuance of 110 million shares at an IPO price of 22.98 yuan per share [1] - The company is controlled by PAN KE, who serves as the chairman and general manager, holding American nationality [1] IPO Details - The total funds raised from the IPO amounted to 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs [1] - The net funds raised exceeded the original plan by 311 million yuan, which was initially set at 2.070 billion yuan [1] - The total issuance costs were 147 million yuan, with CITIC Securities receiving 130 million yuan as underwriting and sponsorship fees [1] Stock Performance - The stock price fell below the IPO price on the first day of trading, with an intraday high of 20.00 yuan, marking the highest price since the listing [1]

Group 1 - The core viewpoint of the news is that Yahui Pharmaceutical experienced a decline in stock price, with a drop of 5.04% to 11.49 CNY per share, and a trading volume of 209 million CNY, resulting in a total market capitalization of 6.563 billion CNY [1] - Yahui Pharmaceutical, established on March 16, 2010, and listed on January 7, 2022, focuses on the research, production, and sales of innovative drugs, with 96.34% of its revenue coming from anti-tumor products [1] Group 2 - Among the top ten circulating shareholders of Yahui Pharmaceutical, Penghua Fund holds a significant position, with its Penghua Medical Technology Stock A (001230) increasing its holdings by 891,300 shares in the second quarter, totaling 6.5441 million shares, which represents 1.73% of the circulating shares [2] - The latest scale of Penghua Medical Technology Stock A is 1.987 billion CNY, with a year-to-date return of 95.32%, ranking 18 out of 4222 in its category, and a one-year return of 111.48%, ranking 146 out of 3798 [2]

Group 1 - The core point of the news is the significant trading activity of Yahu Medicine-U, with a notable block trade occurring on September 5, involving 737,000 shares and a transaction value of 9.0135 million yuan at a price of 12.23 yuan per share [1][2] - The buyer of the block trade was CITIC Securities Co., Ltd. Suzhou Binhe Road Securities Business Department, while the seller was CITIC Securities Co., Ltd. Suzhou Branch [1] - Over the past three months, Yahu Medicine-U has recorded a total of two block trades, with a cumulative transaction value of 11.0204 million yuan [1] Group 2 - As of September 5, Yahu Medicine-U's closing price was 12.23 yuan, reflecting an increase of 2.60%, with a daily turnover rate of 4.24% and a total trading volume of 222.3 million yuan [1] - The stock has seen a net inflow of 927,000 yuan in main funds for the day, while over the past five days, the stock has increased by 5.61%, but there has been a cumulative net outflow of 25.3623 million yuan [1] - The latest margin financing balance for the stock is 240 million yuan, with a decrease of 2.6782 million yuan over the past five days, representing a decline of 1.10% [2] Group 3 - In terms of institutional ratings, one institution has provided a rating for the stock in the past five days, with the highest target price estimated by Pacific Securities at 15.68 yuan as of September 1 [2]

Group 1 - The company, Yahui Pharmaceutical, announced its participation in the 2025 semi-annual performance briefing for the innovative drug industry organized by the Shanghai Stock Exchange [2] - The event is scheduled for September 16, 2025, from 15:00 to 17:00 [2]

Group 1 - On September 5, Yahui Pharmaceutical executed a block trade of 737,000 shares, with a transaction amount of 9.0135 million yuan, accounting for 3.88% of the total trading volume for the day [1] - The transaction price was 12.23 yuan, which was flat compared to the market closing price of 12.23 yuan [1][2] - The trade was facilitated by CITIC Securities Co., Ltd., with the transaction occurring through its Suzhou branch [2]